Blog - Page 565 of 5639 - QualityStocks

MondayOct 30, 2023 12:46 pm

QualityStocksNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Extends Collaboration with Romanian Government on Pivotal EM Initiative

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT and cybersecurity sectors, today announced, together with its local partner, the receipt of a third order by Romania’s Ministry of Interior, further extending the successful partnership and reinforcing their commitment to Romania’s National Electronic Monitoring (“EM”) Project. According to the announcement, the order is valued at approximately $3.4 million and is anticipated to be delivered by the end of the fourth quarter of 2023. “We are excited to extend our collaboration with the Romanian government on this pivotal initiative. The recent order, valued at $3.4 million,…

MondayOct 30, 2023 12:19 pm

QualityStocksNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on 1-for-17 Reverse Stock Split

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, has released information regarding its 1-for-17 reverse stock split. According to the announcement, as a result of the reverse stock split of PaxMedica’s common stock that became effective at 8:03 a.m. ET today, the company’s common stock will begin trading on a split-adjusted basis tomorrow, Oct. 31, 2023, when the market opens. The company noted that its common stock will continue to trade under the existing trading symbol PXMD.…

MondayOct 30, 2023 11:30 am

QualityStocksNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Announces Planned Launch of Its Highly Anticipated Wellness Beverage

Safety Shot (NASDAQ: SHOT) today announced the upcoming direct-to-consumer launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Beginning the first week of December 2023, the beverage will be available for retail purchase at www.DrinkSafetyShot.com and www.Amazon.com. In addition, the company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars in the first quarter of 2024. “We’re very excited to launch Safety Shot through our multichannel strategy designed to dominate e-commerce, quickly win retail shelf space, and establish longstanding ties…

MondayOct 30, 2023 11:15 am

Mountain Top Properties Inc. (MTPP) Is ‘One to Watch’

Mountain Top Properties has issued 250,108,363 shares of common stock as of August 2023 The company will consider selling securities to fund future operations Mountain Top Capital Fund I has a target to raise $75 million to fund its Hamptons projects The company targets minimum ROI of 20% to 30% per transaction Mountain Top Properties (OTC: MTPP) is a diversified real estate holding company that acquires, sells and operates assets through its wholly owned subsidiaries and limited partnerships. The company specializes in property management, property technology (“PropTech”) and real estate redevelopment. Mountain Top Properties was incorporated in 1990 and is…

MondayOct 30, 2023 10:30 am

SenesTech Inc. (NASDAQ: SNES) Geometrically Increases its Addressable Market with the Addition of Evolve(TM) Soft Bait to its Portfolio

SenesTech, a rodent fertility control expert, just announced the launch of its Evolve(TM) Soft Bait, representing an innovative, patent pending, minimum risk alternative treatment to reduce fertility in rats This product adds to the company’s growing line of pest control solutions, such as ContraPest(R), a highly palatable liquid contraceptive bait SenesTech’s management has lauded this milestone, noting how the product, with its non-liquid form, will dramatically increase its addressable market The company plans to market it to professionals as well as directly to consumers through e-commerce and big-box stores SenesTech (NASDAQ: SNES), a rodent fertility control expert and the inventor…

MondayOct 30, 2023 10:28 am

QualityStocksNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events. The event is slated for Nov. 6–8, 2023, in Munich, Germany. According to the announcement, Scinai will showcase both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline. In addition, management will be available to meet with potential partners and clients. Scinai offers a state-of-the-art manufacturing facility for biopharmaceutical…

MondayOct 30, 2023 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Improved Survival Status in ALS Patients Treated with CNM-Au8(R) on Follow-Up Analysis; Announces Peer-Reviewed Study

Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases like ALS In 2019, Clene’s drug candidate, CNM-Au8(R), was selected for the HEALEY ALS Platform Trial, with enrollment commencing in the summer of 2020 Over the years since, Clene has consistently released additional data from the Trial, most recently reporting significant long-term survival improvement among patients treated with CNM-Au8 compared to PRO-ACT historical controls The company also announced the publication of a peer-reviewed study in the nanotechnology-focused journal Small; the study describes CNM-Au8’s mechanism of action Clene received a $45.1…

MondayOct 30, 2023 9:00 am

Longeveron Inc. (NASDAQ: LGVN) Validates Safety and Therapeutic Potential of its Lomecel-B(TM) Lead Investigational Product in its CLEAR MIND Phase 2a Clinical Trial

Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial The study, which explored Lomecel-B(TM)’s effects on mild Alzheimer’s disease, met the primary endpoint of safety on statistical and medical assessment Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, just announced positive top-line results from its CLEAR MIND Phase 2a clinical trial for treating mild Alzheimer’s disease. Most notably, the primary endpoint of safety was met based on statistical and medical assessment, with only one Serious Adverse…

FridayOct 27, 2023 2:41 pm

QualityStocksNewsBreaks – Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Completes High-Definition Survey over PCH Ionic Clay Target IV Project Area

Appia (CSE: API) (OTCQX: APAAF) (FSE: A0I0) today announced that it has completed a high-definition lidar and orthophoto survey across an area of 1,702.50 hectares, which includes the company’s priority Ionic Clay Target IV project area in Goias, Brazil. Metro Cúbico Engenharia LTDA, which is headquartered in São Paulo and made up of a multidisciplinary team of professionals with more than 20 years of experience in various technological areas, was engaged by Appia to complete the survey. “Orthophotos are essential for the efficient management of our drill campaign as they provide high-resolution and accurate visual information with maximum detail,” said…

FridayOct 27, 2023 11:42 am

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Secures $5.2M in Private Placement and Preferred Investment Option Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that it has closed its offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per pre-funded and associated preferred investment option, in a private placement priced at-the-market under Nasdaq rules. Per a previously announced definitive agreement with respect to certain of its outstanding preferred investment options issued in November 2022 and exercisable for 3,272,733…

Site Search

Company Search